Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population.

The effects of radiotherapy (RT) patients' health-related quality of life (HRQoL) are usually compared to those of other treatment modalities instead of HRQoL of the general population in oncological studies. We examined HRQoL of patients with an early prostate cancer (PC) not receiving hormonal treatment up to 3 years after RT using the 15D instrument and the FACT-P questionnaire.

The 15D results were compared to those in the age-standardized general male population (N = 952) using an independent-sample t test. The study population (N = 73) received RT either with 78/2 Gy, 60/3 Gy or 36.25/7.25 Gy fractionation.

No significant differences in the mean total HRQoL scores were found between the RT groups and the general male population at any time point. Patients with PC had more depression (P = .015) and distress (P = .029) than the general male population before the treatment and depression up to 3 months after treatment (P = .019), which did not persist at 3 years. The sexual activity dimension had declined by the end of treatment, and this decline persisted 3 years later (P = .033). Excretion functions were worse compared to those in peers at the end of treatment (P < .001) but no longer at 3 months and later after RT. Regarding the FACT-P, HRQoL remained good at 3 years after RT in all the treatment groups and there were no significant differences between the different RT groups at this time point.

This study demonstrated that patients treated with RT for early PC had similar HRQoL compared to the age-standardized general male population at 3 years after treatment.

Clinical genitourinary cancer. 2022 Aug 03 [Epub ahead of print]

Petri Reinikainen, Miikka Lehtonen, Ilari Lehtinen, Tiina Luukkaala, Harri Sintonen, Pirkko-Liisa Kellokumpu-Lehtinen

Faculty of Medicine and Health Technology, Tampere University, Tampere, Pirkanmaa, Finland; Tampere University Hospital Cancer Center, Tampere, Pirkanmaa, Finland. Electronic address: ., Faculty of Medicine and Health Technology, Tampere University, Tampere, Pirkanmaa, Finland., Faculty of Information Technology and Communication Sciences, Tampere, Pirkanmaa, Finland., Research, Development and Innovation Center, Tampere University Hospital, Tampere, Pirkanmaa, Finland; Faculty of Social and Health Sciences, Tampere University, Tampere, Pirkanmaa, Finland., Department of Public Health, University of Helsinki, Helsinki, Uusimaa, Finland., Faculty of Medicine and Health Technology, Tampere University, Tampere, Pirkanmaa, Finland; Tampere University Hospital Cancer Center, Tampere, Pirkanmaa, Finland.